Holen Sie sich die Stockscreener-App
9.49
0.31%
-0.06
Schlusskurs vom Vortag:
$9.55
Offen:
$9.71
24-Stunden-Volumen:
214.81K
Relative Volume:
0.12
Marktkapitalisierung:
$826.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.09M
KGV:
-4.3733
EPS:
-2.17
Netto-Cashflow:
$-138.01M
1W Leistung:
-7.89%
1M Leistung:
-10.78%
6M Leistung:
+54.55%
1J Leistung:
+22.37%
1-Tages-Spanne:
$9.49
$9.72
1-Wochen-Bereich:
$9.24
$10.43
52-Wochen-Spanne:
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Vergleichen Sie KURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.50 | 831.02M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.19 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.84 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
815.91 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.19 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Eingeleitet | Guggenheim | Neutral |
| 2025-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-14 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Can Kura Oncology Inc. stock sustain institutional interestJuly 2025 Selloffs & Daily Entry Point Trade Alerts - ulpravda.ru
Rate Cut: Will Kura Oncology Inc. stock see insider buyingEarnings Summary Report & Consistent Return Strategy Ideas - ulpravda.ru
Is Kura Oncology Inc. stock affected by interest rate hikesGap Down & Community Verified Trade Signals - ulpravda.ru
Aug Intraday: Is Kura Oncology Inc. stock affected by interest rate hikesWeekly Stock Analysis & Verified Swing Trading Watchlist - ulpravda.ru
Research Analysts Set Expectations for Kura Oncology FY2030 Earnings - MarketBeat
Kura Oncology (NASDAQ:KURA) Stock Price Down 6.1%Here's Why - MarketBeat
Kura Oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Kura Oncology (KURA) Grants Stock Options to New Employees - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Discipline and Rules-Based Execution in KURA Response - Stock Traders Daily
What analysts say about Kura Oncology Inc stockGeopolitical Risk Analysis & Affordable Trading Portfolio - earlytimes.in
Is Kura Oncology Inc a good long term investmentPrice-to-Book Ratio Updates & Maximize Gains Professionally - earlytimes.in
Kura Oncology Stock: Biotech Battleground With High Hopes And Higher Volatility - AD HOC NEWS
Jim Cramer calls Kura speculative but says "It's one of the stronger ones I've seen in a very long time" - MSN
Kura Oncology rises following Jim Cramer comments - MSN
(KURA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Jim Cramer Calls Kura Speculative But Says "It's One of the Stronger Ones I've Seen in a Very Long Time" - Finviz
Kura Oncology shows market leadership with jump to 93 RS rating - MSN
Kura Oncology (STU:KUR) EV-to-FCF : 3.00 (As of Dec. 23, 2025) - GuruFocus
Kura Oncology completes first U.S. commercial sale of KOMZIFTI - MSN
7 Stocks That Were on Jim Cramer’s Radar - Insider Monkey
Kura Oncology (KURA) Shares Surge After FDA Approval and Cramer Endorsement - GuruFocus
Kura Oncology (NASDAQ:KURA) Shares Gap UpHere's Why - MarketBeat
Kura Oncology (STU:KUR) EV-to-OCF : 2.87 (As of Dec. 22, 2025) - GuruFocus
Jim Cramer Discusses Kura Oncology as a Speculative Bet - Finviz
Kura Oncology (HAM:KUR) EV-to-OCF : 2.87 (As of Dec. 21, 2025) - GuruFocus
Jim Cramer discusses Kura Oncology as a speculative bet - MSN
Kura Oncology, Inc. $KURA Stock Position Lifted by Assenagon Asset Management S.A. - MarketBeat
Jim Cramer’s Latest Insights on These 13 Stocks - Insider Monkey
How the Narrative Surrounding Kura Oncology Is Changing After Komzifti Approval - Yahoo Finance
KURA (Kura Oncology) EV-to-OCF : 3.72 (As of Dec. 20, 2025) - GuruFocus
Francis Burrows Sells 23,726 Shares of Kura Oncology (NASDAQ:KURA) Stock - MarketBeat
Kura Oncology Chief Scientific Officer Sells Shares - TradingView — Track All Markets
Why analysts upgrade Kura Oncology Inc. stockWeekly Gains Summary & Daily Volume Surge Trade Alerts - DonanımHaber
Will Kura Oncology Inc. stock see insider buyingJuly 2025 PreEarnings & Low Risk High Win Rate Picks - DonanımHaber
Officer Burrows Files To Sell 23,726 Of Kura Oncology Inc [KURA] - TradingView — Track All Markets
Kura Oncology (NASDAQ:KURA) Shares Down 3.5%Here's Why - MarketBeat
Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval - Finviz
Kura Oncology (KURA) gains momentum as Barclays sees significant potential in Ziftomenib approval - MSN
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AMLSlideshow (NASDAQ:KURA) 2025-12-15 - Seeking Alpha
20 Stocks That Will Double in 2026 - Insider Monkey
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is Kura Oncology Stock Built to Withstand More Downside? - Trefis
EcoR1 Capital LLC Boosts Stock Position in Kura Oncology, Inc. $KURA - MarketBeat
(KURA) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Kura Oncology, Inc. $KURA Shares Sold by Armistice Capital LLC - MarketBeat
Kura Oncology, Kyowa Kirin reveal Komsifti combo data for AML - MSN
Insider Sell: Faheem Hasnain Sells 10,000 Shares of Kura Oncology Inc (KURA) - GuruFocus
Kura Oncology Director Sells 10,000 Shares - TradingView — Track All Markets
Dir Hasnain Sells 10,000 ($109.8K) Of Kura Oncology Inc [KURA] - TradingView — Track All Markets
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):